Ontology highlight
ABSTRACT: Background and aims
The first standard of care in treatment of chronic HCV genotype 1 infection involving directly acting antivirals was protease inhibitors telaprevir or boceprevir combined with pegylated-interferon and ribavirin (triple therapy). Phase III studies include highly selected patients. Thus, treatment response and development of viral resistance during triple therapy in a routine clinical setting needs to be determined. The aims of this study were to investigate treatment outcome and identify sequence variations after triple therapy in patients with chronic HCV genotype 1 infection in a routine clinical setting.Methods
80 patients, who initiated and completed triple therapy in Denmark between May 2011 and November 2012, were included. Demographic data and trea
SUBMITTER: Solund C
PROVIDER: S-EPMC4249835 | biostudies-literature | 2014
REPOSITORIES: biostudies-literature